In a groundbreaking study emerging from the Plastic and Reconstructive Surgery journal, researchers have started to unravel the complex relationship between the growing use of GLP-1 receptor agonists (GLP-1 RAs) and their perioperative effects on patients undergoing body contouring surgeries, specifically panniculectomy procedures. This 10-year retrospective analysis notably sheds light on how these increasingly prescribed medications, primarily used for weight loss and type 2 diabetes management, influence surgical outcomes related to wound healing and postoperative complications.
Body contouring surgery, which includes a variety of procedures aimed at removing excess skin and soft tissue after massive weight loss, has seen a surge in patient numbers in recent years. Among these procedures, panniculectomy stands out as a crucial intervention targeting the removal of loose, hanging skin and fat—known as the pannus—from the lower abdomen. With more patients turning to GLP-1 receptor agonists for metabolic control and weight optimization prior to surgery, plastic surgeons face new challenges understanding how these medications might alter recovery trajectories.
The study conducted at West Virginia University School of Medicine provides valuable insights by analyzing 373 panniculectomy cases spanning 2013 to 2023. Approximately 21.7% of these patients were on GLP-1 medication regimens before their surgeries, a percentage that has climbed steadily in recent years. To ensure the results focused on the isolated impact of these drugs, the researchers excluded individuals undergoing bariatric or hernia repair surgeries, thus honing in on non-bariatric abdominal panniculectomy specifically.
The patient demographics between GLP-1 users and non-users revealed a higher prevalence of type 2 diabetes, hypertension, and chronic obstructive pulmonary disease among those on GLP-1 therapies. Interestingly, body mass index (BMI) did not significantly differ across groups, suggesting that the observed differences in surgical outcomes were not simply due to weight disparities but potentially linked to GLP-1 receptor agonists’ physiological effects.
One of the most compelling findings is the elevated risk of delayed wound healing observed in patients treated with GLP-1 receptor agonists. Data shows that 18.5% of GLP-1 users experienced this complication compared to just 7.5% in the group without these medications. This delay in the reparative process raises critical questions about the underlying mechanisms through which GLP-1 therapies might interfere with tissue regeneration, immune response, or cellular activities crucial for wound closure.
Conversely, an unexpected but equally significant observation was the markedly lower incidence of seroma formation among GLP-1 users, with rates at 4.9%, compared to 14.0% in non-users. Seromas, or fluid accumulations beneath surgical wounds, can prolong recovery and necessitate additional interventions. The reduced seroma risk points towards a potential modulatory role played by GLP-1 RAs on inflammatory pathways or lymphatic drainage, a hypothesis that merits further mechanistic estudios in future research.
Notably, other post-surgical complications such as wound dehiscence (reopening of the wound), infections, and the need for rehospitalization did not differ substantially between patient groups, indicating that while GLP-1 agonists may influence certain healing aspects, they do not exacerbate overall major surgical risks. This nuanced interplay further complicates clinical decision-making but also beckons a deeper understanding of GLP-1 receptor signaling outside glycemic control and weight loss.
Dr. Zachary Andrew Koenig, the lead researcher, emphasizes that these findings highlight a “complex and nuanced interplay” between GLP-1 receptor agonist therapy and soft tissue healing post-panniculectomy. Given West Virginia’s position as a locus for high GLP-1 prescription rates nationally, the institution’s patient cohort provided a unique lens through which to examine these associations, underscoring the broader relevance of this research amidst the expanding use of GLP-1 medications.
The biological underpinnings of GLP-1 receptor agonists suggest multiple pathways potentially contributing to their dualistic effects observed in this study. GLP-1 receptors are expressed in various peripheral tissues, including the skin and immune cells, indicating that their activation might influence inflammation, cellular proliferation, angiogenesis, and extracellular matrix remodeling—processes central to wound healing. Yet, the differential impact on wound healing delays versus seroma formation reduction underscores that these pathways might be selectively modulated, which has significant implications for perioperative management.
Given the increasing integration of GLP-1 receptor agonists into patient care for metabolic and weight-related conditions, plastic surgeons and multidisciplinary care teams must evaluate the timing, dosing, and monitoring of GLP-1 therapies around the surgical window carefully. Proactive management strategies could involve enhanced wound surveillance, tailored perioperative protocols, or temporary cessation strategies, all aimed at optimizing healing outcomes without compromising the metabolic benefits these medications provide.
The study’s authors advocate for more comprehensive investigations to delineate formal clinical guidelines that can inform how GLP-1 receptor agonists should be used in the context of plastic and reconstructive surgery. This includes prospective trials to validate the retrospective findings, mechanistic studies to decode molecular effects on wound healing, and multidisciplinary approaches to balance metabolic optimization with surgical safety.
In conclusion, while GLP-1 receptor agonist therapy does not appear to increase major surgical risks, the subtle yet significant effects on wound healing require heightened clinical vigilance and adaptive care models. This research marks a critical advancement in understanding the perioperative implications of a drug class that is rapidly reshaping the landscape of metabolic and weight management. As the plastic surgery community confronts these evolving challenges, ongoing research and guideline development will be paramount in ensuring safe and effective patient outcomes.
This study not only represents a milestone in surgical outcomes research but also provides a roadmap for addressing the complex realities of integrating novel pharmacotherapies into established surgical disciplines. The emerging evidence emphasizes the importance of personalized medicine approaches where surgical plans are attuned not only to anatomical needs but also to the dynamic interplay of pharmacologic treatments and tissue biology.
Subject of Research: Effects of GLP-1 receptor agonists on surgical outcomes and wound healing in non-bariatric abdominal panniculectomy patients.
Article Title: Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis
News Publication Date: 26-Mar-2026
Web References:
https://journals.lww.com/plasreconsurg/fulltext/2026/04000/perioperative_glp_1_receptor_agonist_use_and.14.aspx
https://www.plasticsurgery.org/cosmetic-procedures/body-contouring
https://www.plasticsurgery.org/reconstructive-procedures/panniculectomy
Keywords: GLP-1 receptor agonists, panniculectomy, body contouring surgery, wound healing, surgical complications, perioperative management, plastic surgery, metabolic therapy, type 2 diabetes, delayed wound healing, seroma formation, surgical outcomes.
